PMID- 37909331
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20240210
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 133
IP  - 21
DP  - 2023 Nov 1
TI  - Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung 
      cancer.
LID - 10.1172/JCI174171 [doi]
LID - e174171
AB  - Although subsets of patients with lung squamous cell carcinoma (LSCC) benefit 
      from immunotherapy, there are few effective molecularly targeted treatments for 
      LSCC. Fibroblast growth factor receptor (FGFR) inhibitors provide a therapeutic 
      option for patients with LSCC harboring FGFR aberrations, but their therapeutic 
      efficacy has been limited to date. In this issue of the JCI, Malchers et al. 
      identified tail-to-tail rearrangements, either within or near FGFR1, that are 
      associated with FGFR1 dependency and sensitivity to FGFR inhibition in LSCC. 
      These results may help improve the selection of patients with LSCC who are most 
      likely to benefit from treatment with FGFR inhibitors.
FAU - Makinen, Netta
AU  - Makinen N
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts, USA.
AD  - Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, 
      USA.
FAU - Meyerson, Matthew
AU  - Meyerson M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts, USA.
AD  - Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, 
      USA.
AD  - Departments of Genetics and Medicine, Harvard Medical School, Boston, 
      Massachusetts, USA.
LA  - eng
GR  - R35 CA197568/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Editorial
DEP - 20231101
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
RN  - EC 2.7.10.1 (FGFR1 protein, human)
SB  - IM
CON - J Clin Invest. 2023 Nov 1;133(21):null. PMID: 37606995
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/genetics/metabolism
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/metabolism
MH  - *Carcinoma, Squamous Cell/drug therapy/genetics/metabolism
MH  - Receptor, Fibroblast Growth Factor, Type 1/genetics/metabolism
MH  - Genomics
MH  - Epithelial Cells/metabolism
PMC - PMC10617760
COIS- Conflict of interest: MM receives research support from Bayer, Ono, and Janssen; 
      patent licensing royalties from Bayer (patents including US patent no. 
      11,427,553, "Dihydrooxadiazinones"; US patent no. 11,339,157, 
      "4H-pyrrolo[3,2-c]pyridin-4-one derivatives"; US patent no. 11,207,320, 
      "Compositions and methods for cancer expressing PDE3A or SLFN12"; US patent no. 
      11,142,522, "Compounds, compositions and methods for cancer treatment"; US patent 
      no. 10,966,986, "Compounds, compositions and methods for cancer patient 
      stratification and cancer treatment"; and US patent no. 9,890,127, "Compounds and 
      compositions for the treatment of cancer," as well as patents pending) and 
      LabCorp (US patent nos. 10,669,589; 10,000,815; 9,035,036; 8,465,916; 8,105,769; 
      7,964,349; and 7,294,468; all titled "Method to determine responsiveness of 
      cancer to epidermal growth factor receptor targeting treatments," as well as 
      patents pending); and serves as a scientific advisory board member and consultant 
      with ownership interest in and income for Delve Bio, Interline, and Isabl.
EDAT- 2023/11/01 12:43
MHDA- 2023/11/02 12:42
PMCR- 2023/11/01
CRDT- 2023/11/01 06:55
PHST- 2023/11/02 12:42 [medline]
PHST- 2023/11/01 12:43 [pubmed]
PHST- 2023/11/01 06:55 [entrez]
PHST- 2023/11/01 00:00 [pmc-release]
AID - 174171 [pii]
AID - 10.1172/JCI174171 [doi]
PST - epublish
SO  - J Clin Invest. 2023 Nov 1;133(21):e174171. doi: 10.1172/JCI174171.